Black Diamond Therapeutics Inc (nasdaq:BDTX) Share Price

Company Profile

Business description
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
Contact
245 First Street
18th Floor
CambridgeMA02142
USA
T: +1 617 252-0848
https://www.blackdiamondtherapeutics.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
21

Recommended

International expansion is a distraction from valuable local business.

Roy Van Keulen | 14 May 2026

The chipmaker’s IPO priced at $185, well above its initial range, and opened trading at an eye-popping $350.

Jacob Robbins | 14 May 2026

How the most traded shares in April stack up against our analysts views.

Tyger Fitzpatrick | 14 May 2026

Index	Last price	Change	% Change
All Ordinaries	8,870.60	46.70	-0.52%
CAC 40	7,952.55	129.72	-1.61%
DAX 40	23,950.57	505.69	-2.07%
Dow JONES (US)	49,526.17	537.29	-1.07%
FTSE 100	10,195.37	177.56	-1.71%
HKSE	25,962.73	426.31	-1.62%
NASDAQ	26,225.14	410.08	-1.54%
Nikkei 225	61,409.29	1,244.76	-1.99%
NZX 50 Index	12,965.01	60.06	-0.46%
S&P 500	7,408.50	92.74	-1.24%
S&P/ASX 200	8,630.80	42.70	-0.49%
SSE Composite Index	4,135.39	42.53	-1.02%